

## Document History

<b>Summary of Changes</b> <b>MarkVCID2 Case Report Forms (CRFs)</b>			
Version	Description of Changes	Reason for Change	Version Date
1.0	N/A – original version	N/A	4.19.2022
2.0	<ul style="list-style-type: none"> <li>p. 3: Added single self-report question for screening for Subject Cognitive Decline (SCD)</li> <li>p. 3-4: Added guidance on administering Short eCog-12 to the participant when screening for and confirming SCD</li> <li>p.4: Added clarification to CDR threshold for mild dementia to be CDR: Global Score of 0.5 or 1</li> <li>p. 4: Added CADASIL to the list of excluded neurologic conditions</li> </ul>	To describe study procedures in more detail.	5.23.2022
3.0	<ul style="list-style-type: none"> <li>p. 3-4: Added clarification that when Short eCog-12 criteria are used for preliminary diagnosis of subjective cognitive decline, the criteria are based on a score of <math>\geq 3</math> <u>on any single item</u></li> <li>p. 30: Added AVLT as a word list learning test option</li> <li>p. 32: Updated list of reasons for not completing the Co-Participant or Informant Questionnaire</li> <li>p. 33: Added field to capture whether CDR was scored with the input of an informant</li> <li>p. 37-38: Updated list of reasons for not completing eCog-12: Informant and NPI-Q forms</li> <li>p. 43: Added fields to capture deviations to the imaging protocol and Fazekas rater's first and last name initials</li> <li>p. 44: Added page for the assessment of microbleeds and lacunar infarcts</li> </ul>	To describe study procedures in more detail and add fields related to microbleed and lacunar infarct data per the updated protocol.	8.18.22
4.0	Revised CRFs with updated exclusion criteria including: <ul style="list-style-type: none"> <li>Confounding Neurologic, Psychiatric, or Medical Disease (pg. 5):               <ul style="list-style-type: none"> <li>Current or expected use of anti-amyloid immunotherapy at baseline.</li> </ul> </li> <li>Contraindications to CVR including COPD, asthma, or other respiratory conditions requiring oxygen therapy or current use of medications.</li> </ul>	To clarify current study procedures	1.26.24